Daniel C. Danila

Memorial Sloan Kettering Cancer Center — United States

Medicine · Health Sciences

46h-index15.0kcitations378works1.12yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Prostate Cancer Treatment and Research(294), Radiopharmaceutical Chemistry and Applications(75), Cancer Genomics and Diagnostics(64), Cancer, Lipids, and Metabolism(60), Cancer Immunotherapy and Biomarkers(32)

Publications378 total

Table S1 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer
2025Open Access
Figure S2 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer
2025Open Access
Figure S4 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer
2025Open Access
Table S3 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer
2025Open Access
Figure S3 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer
2025Open Access
Figure S1 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer
2025Open Access
Table S4 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer
2025Open Access
Table S2 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer
2025Open Access
A phase 1b/2 study of intermittent talazoparib plus temozolomide in patients with metastatic castration-resistant prostate cancer and no mutations in DNA damage response genes
Investigational New Drugs·2025· 1 citedOpen Access
BCL2 drives castration resistance in castration-sensitive prostate cancer by orchestrating reciprocal crosstalk between oncogenic pathways
Cell Reports·2025· 2 citedOpen Access
Does cytoplasmic AR-V7 circulating tumor cell (CTC) detection add utility in predicting AR pathway inhibitor benefit in men with mCRPC? A retrospective analysis of the PROPHECY study.
Journal of Clinical Oncology·2025
Molecular characterization of STEAP1 and -2 in advanced prostate cancer.
Journal of Clinical Oncology·2025
A phase 1b, open-label, multicenter study of xaluritamig in patients with biochemical recurrence of prostate cancer after definitive therapy.
Journal of Clinical Oncology·2025· 1 cited
Supplemental Figure 4 from Microsatellite Instability, Tumor Mutational Burden, and Response to Immune Checkpoint Blockade in Patients with Prostate Cancer
2024Open Access
Supplemental Table 3 from Microsatellite Instability, Tumor Mutational Burden, and Response to Immune Checkpoint Blockade in Patients with Prostate Cancer
2024Open Access
Supplemental Table 3 from Microsatellite Instability, Tumor Mutational Burden, and Response to Immune Checkpoint Blockade in Patients with Prostate Cancer
2024Open Access
Supplemental Figure 3 from Microsatellite Instability, Tumor Mutational Burden, and Response to Immune Checkpoint Blockade in Patients with Prostate Cancer
2024Open Access
Supplemental Table 2 from Microsatellite Instability, Tumor Mutational Burden, and Response to Immune Checkpoint Blockade in Patients with Prostate Cancer
2024Open Access
Data from Microsatellite Instability, Tumor Mutational Burden, and Response to Immune Checkpoint Blockade in Patients with Prostate Cancer
2024Open Access
Supplemental Figure 1 from Microsatellite Instability, Tumor Mutational Burden, and Response to Immune Checkpoint Blockade in Patients with Prostate Cancer
2024Open Access
page 1 of 19Next →

Frequent Co-authors

Howard I. Scher(37), Martin Fleisher(20), Michael J. Morris(14), Dana E. Rathkopf(13), Glenn Heller(12), Nikolaus Schultz(8), Susan F. Slovin(8), Charles L. Sawyers(7), Steven M. Larson(7), Johann S. de Bono(7), David B. Solit(6), Aseem Anand(6), Hans Lilja(6), Michael F. Berger(5), Wassim Abida(5), Karen A. Autio(5), Hebert Alberto Vargas(5), Thian Kheoh(5), Arturo Molina(5), David Olmos(5)